Editor's letter

Issue 146 • September 2024

Don’t miss out – sign up to our free industry-leading magazine and newsletters

Cover image: Lithium ore a facility in Australia. Credit: Carla Gottgens/Bloomberg

Welcome to the latest issue of Pharmaceutical Technology Focus magazine

The success of glucagon-like peptide receptor antagonists (GLP-1RAs) over the last few years stands out in the pharmaceutical landscape due to this class’s potential to grow in more than one disorder. While the leading GLP-1RAs were initially approved for type 2 diabetes, they have since been indicated for wider groups of patients. 

This month’s cover story looks at how pharmaceutical and biotech companies are strategically approaching the wide umbrella of metabolic disorders to plan drug development. 

Also in this issue, an interview delves into NVIDIA’s strategy for growing its artificial intelligence (AI) prowess in the healthcare sector, and a feature investigates the robust dealmaking in the antibody drug conjugate (ADC) space. 

All this, along with the latest news and deals in the pharmaceutical landscape.

Manasi Vaidya, editor

Go to article: Home | Pharma casts a wide net to hook opportunities in metabolic disordersGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: DatwylerGo to article: BiomeBank Company InsightGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Molnar-Institute Company InsightGo to article: Molnar-InstituteGo to article: Allpack Group AG Company InsightGo to article: Science4TechGo to article: ZETAGo to article: In DepthGo to article: Pharma casts a wide net to hook opportunities in metabolic disorders Go to article: Alzheimer’s: drug delivery and the blood brain barrier conundrumGo to article: Era of ADCs: Pharma companies innovate to stand out in a buzzing marketGo to article: AbbVie’s Humira loss of exclusivity has been a missed opportunity for competitorsGo to article: How NVIDIA grew with the healthcare market instead of pushing into it Go to article: Sponsored SupplementsGo to article: FaravelliGo to article: Simtra BioPharma SolutionsGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Excellence Awards 2024: TrialHubGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue